A short, curated read of what happened across the industry this week: FDA approvals, clinical trial milestones, funding rounds, grants, and deals. Pulled from public industry data, not personalized to any one company or account.
Week of Jul 20 - Jul 26, 2026
This week tilted toward market entry and capital deployment, with less weight on the clinical trial side than the past few weeks. What caught our eye is the clustering of regulatory wins and financing moves, which points to a particular moment: companies are locking in European approvals and raising money to scale manufacturing and commercial operations in parallel.
Three therapies moved toward or into European markets this week. Roche's Susvimo, a continuous-release ranibizumab treatment for age-related macular degeneration delivered through a small implant, won a positive recommendation from the European Medicines Agency's committee, clearing the path for a final approval decision. NewAmsterdam Pharma and Menarini Group received the same committee endorsement for Ubeslo and Evlarco, obicetrapib monotherapy and a fixed-dose combination with ezetimibe for lipid management. These are not the same disease or the same modality, but they share a pattern: both therapies are moving into competitive markets where manufacturing complexity and market-access strategy matter as much as the science. For the companies that handle regulatory submissions, supply-chain planning, and reimbursement negotiations in Europe, these wins point to a busy stretch ahead.
Dyne Therapeutics closed an upsized public offering of roughly 23.8 million shares at $20.50 per share, raising approximately $431 million in gross proceeds. That scale of capital typically funds clinical development, manufacturing scale-up, and the infrastructure needed to commercialize therapies. Separately, Scribe Therapeutics announced pricing of its upsized initial public offering, signaling investor appetite for gene-editing platforms as they move toward clinical reality. Meanwhile, Nuvectis Pharma secured marketing approval in China for ciprocopan, an oral complement inhibitor for paroxysmal nocturnal hemoglobinuria, a rare blood disorder. That approval opens a large patient population in Asia and diversifies revenue geography for a rare-disease program. The thread across these moves is capital flowing toward companies that are ready to manufacture at scale and enter new markets simultaneously.
Three large Phase 3 trials remain actively recruiting across thousands of sites: the National Cancer Institute's breast cancer study spanning 1,569 sites, AstraZeneca's respiratory infection trial across 464 sites, and Incyte's hidradenitis suppurativa rollover study at 318 sites. These trials represent sustained operational demand, but they are not the week's dominant story. The public record shows what these companies chose to announce this week, not always the reasoning behind the timing of those announcements. Regulatory approvals and financing rounds tend to be the moves companies put on record when they are confident in their path forward; the why usually emerges over the next few weeks as execution unfolds.
One short email a week on what moved across the life science industry. No spam, unsubscribe any time.